552c7ae14ClaimYounger patients should receive priority when lifesaving treatment is scarceAgreeDisagree2
552c7ae14ClaimDoctors should be allowed to prescribe undisclosed placebos when no effective treatment existsAgreeDisagree20
552c7ae14ClaimThe psychological effect on a patient of receiving a drug prescribed by a doctor is beneficial in itselfAgreeDisagree
552c7ae14ClaimParents should be allowed to select embryos against adult-onset inherited diseaseAgreeDisagree
552c7ae14ClaimA placebo's psychological effect is driven by the patient's confidence in the medical professional and their belief that they are receiving a cureAgreeDisagree
552c7ae14ClaimSatralizumab is a humanized monoclonal antibody designed to bind to soluble and membrane-bound interleukin-6 receptors, inhibiting interleukin-6-mediated inflammatory signalingAgreeDisagree
552c7ae14ClaimThyroid eye disease is an inflammatory autoimmune condition affecting an estimated 16 women and 3 men per 100,000 population, commonly occurring in people with hyperthyroidismAgreeDisagree
552c7ae14ClaimSatralizumab is the first and only at-home subcutaneous treatment cleared by the FDA for adults with thyroid eye diseaseAgreeDisagree
552c7ae14ClaimPrior to satralizumab's approval, the FDA approved two intravenous thyroid eye disease treatments targeting the insulin-like growth factor 1 receptor: teprotumumab in 2020 and veligrotug in June 2026AgreeDisagree
552c7ae14ClaimSatralizumab was initially approved by the FDA in 2020 for neuromyelitis optica spectrum disorder, a rare neuroinflammatory conditionAgreeDisagree
552c7ae14ClaimSatralizumab can be self-administered subcutaneously by a patient or caregiver following initial training from a healthcare providerAgreeDisagree
552c7ae14ClaimAlthough satralizumab's SatraGO-1 trial failed to meet its primary efficacy endpoint at week 24, satralizumab received approval based on efficacy results from satralizumab's SatraGO-2AgreeDisagree